>>> Brokers Upgrades & Downgrades - 22/04/2014

>>> Up
*ATOS RAISED TO BUY VS NEUTRAL AT UBS
*EVRAZ RAISED TO NEUTRAL VS UNDERWEIGHT AT JPMORGAN
*LAMPRELL RAISED TO BUY VS NEUTRAL AT CITI
*RUSAL RAISED TO BUY VS NEUTRAL AT GOLDMAN
*STEINHOFF RAISED TO BUY VS NEUTRAL AT BOFAML

>>> Down
*DEUTSCHE BANK CUT TO NEUTRAL VS BUY AT UBS
*ENI CUT TO NEUTRAL VS BUY AT UBS
*INGENICO CUT TO UNDERWEIGHT VS EQUALWEIGHT AT MORGAN STANLEY
*LANXESS CUT TO HOLD FROM BUY AT BANKHAUS LAMPE

>>> PT Change

>>> Initiation
*BERKELEY RESOURCES RATED NEW BUY AT NUMIS
*CIRCASSIA RATED NEW OVERWEIGHT AT JPMORGAN, PT 390P
*ERICSSON RATED NEW MARKET PERFORM AT RAYMOND JAMES
*MAGNA INTERNATIONAL RATED NEW NEUTRAL AT UBS, PT $101
*PETS AT HOME RATED NEW BUY AT GOLDMAN, PT 242P
*POUNDLAND GROUP RATED NEW NEUTRAL AT JPMORGAN

>>> Call

>>> Allergan would evaluate Valeant offer if received

Allergan would evaluate Valeant offer if received

Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") yesterday (21 April) became aware of public filings made by Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") regarding Valeant's purported intention to propose a merger in which the Company's stockholders would receive a combination of Valeant common shares and cash in exchange for the outstanding shares of the Company's common stock.

The Company's Board of Directors (the "Board") intends to evaluate any such offer or proposal, if received, in consultation with its financial and legal advisors, and the Board will thereafter advise the Company's stockholders of its position regarding any such offer or proposal, as well as its reasons for that position. The Company's stockholders do not need to take any action at this time.

Allergan has had no discussions with either Valeant or Pershing Square with respect to this matter. The Company notes that neither Valeant nor Pershing Square has put forward an offer or proposal with respect to any type of merger transaction involving the Company, and the public disclosure materials filed by those entities suggest that they have expressly reserved the right to terminate their business relationship should no such offer be forthcoming.


Source Company Press Release

>>> US After Hours

After Hours Summary: NFLX +6.6%, RCII +4.0%, CE +3.2%, RMBS -6.5%, BBCN -0.1% following earnings/guidance

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings: NFLX +6.6%, RCII +4.0%, CE +3.2%, CYS +1.3%

Companies trading higher in after hours in reaction to news: AGN +21.4% (Pershing Square and Valeant Pharmaceuticals (VRX) form joint venture to pursue acquisition of AGN), VRX +8.8% (see above), IMUC +8.4% (announced ICT-107 Phase 2 data abstract accepted for oral presentation at the 2014 ASCO annual meeting), RTK +4.1% (Blackstone Group discloses 16.5% stake in 13D filing), RVNC +3.1% (announced positive results from the RT002 Phase 1/2 study in glabellar (frown) lines), SGMS +1.5% (signed a contract with La Francaise des Jeux, the operator of the French National Lottery), KORS +1.2% (Lone Pine Capital disclosed 5.5% stake in 13G), GILD +1.0% (NDA for cobicistat and elvitegravir for HIV therapy accepted by FDA)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: RMBS -6.5%, BBCN -0.1%

Companies trading lower in after hours in reaction to news: ALSN -2.0% (announced sale of 25 mln shares of common stock by selling stockholders), MLNX -0.8% (ITC ruled co does not infringe Avago's (AVGO) laser driver patent), EFC -0.7% (filed for $750 mln mixed securities shelf offering)

>>> Asian Update

Asian Market Update: Australian treasurer scoffs at RBA's neutral stance; Netflix sets the pace for beaten down momentum stocks


***Economic Data***
- (AU) AUSTRALIA FEB CONFERENCE BOARD LEADING INDEX M/M: 0.3% V 0.2% PRIOR
- (TW) TAIWAN MAR UNEMPLOYMENT RATE: 4.1% V 4.1%E
- (SL) SRI LANKA LEAVES REVERSE REPO RATE UNCHANGED AT 8.00% (EXPECTED); LEAVES REPURCHASE RATE UNCHANGED AT 6.50% (EXPECTED)
- (US) NORTH AMERICA MAR SEMI BOOK/BILL RATIO: 1.06 (4-month high) V 1.01 PRIOR

Market Snapshot (as of 03:30 GMT):
- Nikkei225 +0.3%, S&P/ASX +0.4%, Kospi +0.1%, Shanghai Composite -0.1%, Hang Seng -0.2%, Jun S&P500 flat at 1,864, Jun gold -0.1% at $1,287, May crude oil -0.1% at $104.24/brl

***Highlights/Observations/Insights***
- Asian indices are mixed with largely the same themes dictating sentiment as in overnight trade. Nikkei225 is outperforming, boosted by continued modest pressure on the Yen, while Shanghai Composite remains weighed down by speculation over renewed mainland IPOs. Note that the Shanghai index fell some 1.5% on Monday - the biggest decline in 6 weeks. S&P/ASX is also up a respectable 0.4% in afternoon trade, catching up after extended holiday weekend.

- Australia Treasurer Hockey expressed increasing dissatisfaction with the entrenched neutral stance by the RBA. Hockey noted that the upward pressure in AUD makes it harder to manage the economy, as the conservative coalition continues to struggle with measuring up to budget expectations. After falling below $0.87 at the start of the year, AUD/USD has been in a well-defined uptrend for 3 months, and analysts are beginning to speculate over a return to parity. Conditions will likely be much more volatile tomorrow when Australia puts out its quarterly CPI data and China releases HSBC flash manufacturing PMI.

- Japan was also proactive with an eye toward a generally stalled sell-off in its currency, promoting new members to Japan Pension Fund (GPIF) committee to pursue PM Abe's goal of a more aggressive investment strategy. Waseda University professor Yonezawa - known for arguing for a bolder approach to asset management - was reported to take the reins as the next head of investment committee, which would then presumably rotate some of its holdings away from fixed income and toward riskier equity/ETF assets, thus contributing to achieving the BOJ objective of 2% inflation.

- Only 24 hours after a high-profile speculation of M&A in the healthcare space (Pfizer/AstraZeneca), Bill Ackman of Pershing Square partnered with Valeant in pursuit of a bid for Allergan. Pershing put out a filing indicating it has built its stake to 9.7%, with an indicated cash component of the bid coming at $15B. Allergan responded later in the day, noting it is aware of recent filings but has had no discussions with either Valeant or Pershing Square with respect to this matter.

- Netflix is up nearly 7% in extended session after Q1 earnings. Revenues were in line and EPS was a 3-cent beat relative to estimates, however the company also posted strong adds in the US streaming segment and announced a price increase, having successfully tested for elasticity of its offerings in Ireland. The company is betting US consumers would not drop its service even if it costs $1-2 more per month, and that it can avoid a debacle the last time it announced an update to its price scheme. Shares traded up above $370 afterhours, which is up nearly 20% from a multi-month low seen only a week ago.

***Fixed Income/Commodities/Currencies***
- (CN) PBoC to drain CNY100B in 28-day repos (19th consecutive drain)
- SLV: iShares Silver Trust ETF daily holdings rise to 10,282 tonnes from 10,229 tonnes prior (highest level since Dec 10th)
- GLD: SPDR Gold Trust ETF daily holdings fall 3.0 tonnes to 792.1 tonnes (lowest since 790.5 on Jan 28th)
- USD/CNY: (CN) PBoC sets yuan mid point at 6.1610 v 6.1591 prior setting (weakest Yuan setting since Sept 10th)

US markets:
- AGN: Pershing Square (Bill Ackman) and Valeant said to be partnering to pursue a takeover of Allergan - financial press; Pershing Square confirms 9.7% stake in Allergan; confirms teamed with Valeant for intended offer for Allergan - filing; +17.4% afterhours
- NFLX: Reports Q1 $0.86 v $0.83e, R$1.27B v $1.27Be; NFLX: Exec: modest price increases will help improve content; will make sure to grandfather current customers "cleanly"; +6.8% afterhours
- RCII: Reports Q1 $0.57 (ex $0.03 charge) v $0.55e, R$834M v $845Me; +4.6% afterhours
- CE: Reports Q1 $1.33 v $1.21e, R$1.71B v $1.68Be; "Raises FY14 earnings outlook"; +3.6% afterhours
- FB: Credit Suisse Raised FB to Outperform from Neutral, price target: $87; +1.0% afterhours
- RMBS: Reports Q1 $0.17 v $0.02e, R$78.3M v $72.8Me; -7.7% afterhours

Notable movers by sector:
- Consumer Discretionary: Great Wall Motor 2333.HK -8.7% (Q1 results); Sichang Changhong Electric 600839.CN -6.5% (Q1 results); Citic Offshore Helicopter 000099.CN -3.8% (Q1 results)
- Energy: Anton Oilfield Services Group 3337.HK +4.8% (Q1 new orders); Inner Mongolia Pingzhuang Energy 000780.CN -3.6% (FY13 results); Oil Search Ltd OSH.AU +0.6% (Q1 results); Paladin Energy Ltd PDN.AU +1.1% (quarter op results); Tokyo Gas 9531.JP +1.2% (share repurchase plans)
- Industrials: Air China 753.HK -6.1% (profit warning)
- Healthcare: Tasly Pharmaceutical Group 600535.CN -5.6% (Q1 results)
- Utilities: TEPCO +3.8% 9501.JP (refinancing plans)

The Myth of the Stock Picker's Market



If you believe the Wall Street sell-side orthodoxy, we've moved into a "stock picker's market."
That's because the returns of Standard and Poor's 500 stocks have begun to vary more widely from each other this year than in recent years when they were moving more in lockstep. The inference is that it's easier to beat the market during these periods of higher dispersion.
But according to Rick Ferri, an investment advisor and index-fund zealot, "There is no evidence to support the notion that active stock selection is easier when there is wide dispersion among individual stock returns."
He cites a new study, "Dispersion: Measuring Market Opportunity," by S&P Dow Jones, which suggests that the probability that actively managed mutual funds will outperform the market are no higher during periods of high dispersion than low dispersion.
According to study, dispersion gives us a way only to measure the potential value of stock selection ability.
Ferri writes that the study shows there is little relationship between large-cap U.S. actively managed fund success and dispersion of stocks in the S&P 500. "Although there is higher dispersion among active fund returns during periods of high stock market dispersion, this fund dispersion does not increase the likelihood of outperformance by active managers within the large-cap U.S. market segment."
I didn't need a study to understand that truth. Common sense should tell us that wide variance or dispersion among stock returns doesn't mean that we will have a better chance to beat averages. It might tell us that we have a better chance to vary from an average, but that greater variance can give the stock picker a result that is lower than a benchmark just as easily as it gives a result that is above the benchmark.
Writes Ferri: "It's often helpful to step back from the data and think about things logically. Why should there be a greater percentage of active fund managers who outperform during periods of high dispersion? Does skill increase during these periods? Are there more opportunities to outperform? I find these arguments suspect."
Meanwhile, Netflix (ticker: NFLX) reported first-quarter results after hours Monday which were better than expected. The stock earned 86 cents a share, three pennies more than the Thomson Reuters consensus. The company also announced that it plans by July to increase its U.S. prices for new members by a dollar or two a month, from the current $7.99 a month level, after seeing limited impact from a price increase in Ireland.
Not surprisingly, the stock was up 7% on Monday evening, which comes after the stock has showed a nice rally starting last Wednesday. Before that, the stock had lost almost a quarter of its value over the previous month amid a downdraft for a number of glamor tech stocks.
Almost two weeks, this column referenced a bearish argument against Netflix, mostly built around "exploding content costs."
But a piece that ran Monday on Fortune's website makes four long-term arguments for the video-streaming service, according to a recent study by RBC Capital Markets.
Among the arguments: "Most Netflix customers are happy with the service, according to the survey. Overall Netflix satisfaction levels are now at record levels, with 66% of current subscribers responding that they are either "extremely satisfied" or "very satisfied" with their service, up from 62% one year ago," the report states. In addition, "Netflix subscribers are increasingly less likely to leave the service, the survey found, with 69% of current subscribers "not at all likely" to cancel their subscriptions in the next three months, up from 66% one year ago."
As a satisfied Netflix customer who would gladly pay a buck or two more a month for the service, I buy the arguments of RBC Capital Markets.
I'll close the column with a perceptive piece by New Yorker financial writer James Surowiecki who identifies a major reason why investors have sold off the biotech sector in the past month – the fear that the federal government will step in and regulate prices.
"The selloff can be explained to some extent as a market correction and part of a wider flight from risk," he adds. But the real story, he contends, is that government could eventually step in to lower prices of expensive medications. He cites the example of revolutionary new hepatitis-C drug, Sovaldi, developed by Gilead. "A single dose of the drug costs a thousand dollars, which means that a full, twelve-week course of treatment comes to more than eighty grand," he adds.
"Biotech, in other words, may become the victim of its own success: the bigger the profits, the bigger the likelihood of regulation," Surowiecki writes. "The uproar over Sovaldi may, somewhere down the line, help contain drug prices. But in the short run it could well make drugs even more expensive. And that's what you call a serious side effect."

FT : As Goldman glister fades restoring brilliance is t

As Goldman glister fades restoring brilliance is tough

Goldman Sachs remained a partnership long after its rivals went public. When it finally took the plunge, in 1999, it revealed almost absurd levels of profitability: returns on equity of more than 40 per cent in some years, twice as high as its rivals. A decade later, under chief executive Lloyd Blankfein, Goldman avoided the fate of Lehman Brothers, Merrill Lynch and Bear Stearns. Call it superior risk management. Credit the “big short” that Goldman placed on the mortgage market. Or lay it on Goldman’s unofficial motto to be “long-term greedy”.

Surviving the crisis and then immediately thriving was the crowning glory of an investment bank that has inspired more respect, envy, fear and loathing than any other. But over the past few quarters something strange has happened: Goldman is starting to look unexceptional. Reporting first-quarter results last week, chief financial officer Harvey Schwartz was able to boast of a “pretty dominant performance in investment banking,” a “quite solid performance in fixed income” and a return on equity that was “the highest in our peer group”. All true. But this is hardly setting investors’ hearts racing or leaving rivals quaking in their boots. Goldman had its best quarter in investment banking since 2007. But there were notes of caution even here. It missed out on big deals, sometimes by backing the wrong horse, such as on the Time Warner-Comcast merger. This is an occupational hazard. But it is also ceding ground to rivals. Goldman still has great investment bankers. It’s just that others have closed the gap. In the much bigger business of fixed income trading, Goldman’s performance was “quite solid” only by much reduced expectations. Four years ago Goldman made twice as much money trading bonds, currencies and commodities and was the top earner on Wall Street. This year it was beaten by three of its four US competitors. On profitability, the return on equity was certainly better than the rest. But 10.9 per cent would have caused paroxysms of anguish among Goldman executives a few years ago. There are perfectly reasonable excuses. Goldman like other large banks has been forced to take on more, loss-absorbent equity. This bulwark against catastrophe is also a barrier to outsized profits. But people hire, work for and invest in Goldman because it can swim against a strong tide. On a media call last week – one welcome sign of an end to exceptionalism is that Goldman publicly answered questions from reporters after several quarters of being the only bank not to do so – Mr Schwartz suggested Goldman would win a war of attrition. Take commodities, where Barclays, JPMorgan Chase and Morgan Stanley are retreating because of new regulations. Goldman can hope to stay the course and exploit the situation. But it is hard to believe that these pockets of capitulation will free enough revenues for Goldman to return to its heyday – apart from the fact that repricing by a handful of winners might provoke regulators or prompt clients to find other means of transacting business. Meanwhile, Goldman has regulatory headaches that it cannot escape. Its big direct investing arm has been hemmed in by regulations including the Volcker rule, which bans proprietary trading and limits ownership of private equity funds. There are advantages to being less distinctive. One is removing the target on your back. In 2010 Goldman was pushed into paying $550m by the Securities and Exchange Commission to settle allegations it provided incomplete information to investors in a complex mortgage-based security. It took regulators longer to tackle the much more flagrant abuses by banks that actually originated defective mortgages, which Goldman did not do, and package them into securities, in which Goldman was a smaller player. But this must be a minor consolation for the loss of exceptionalism. On a 10-year basis, compared with all its US peers, and the big Europeans – Barclays, Deutsche Bank, Credit Suisse and UBS – Goldman is the best-performing stock. Take the same peer group this year and it is the worst. On other measures where Goldman used to be dominant, such as price-to-book value, it is now merely near the top. Investors are no longer paying for Goldman as if it is exceptional. Restoring the brilliance premium is going to be a tough ask for the remainder of Mr Blankfein’s reign.